APA (7th ed.) Citation

S, P., M, C., B, H., AO, Y., P, W., R, N., . . . L, E. (2023). Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN). Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 64(2), 221. https://doi.org/10.2967/jnumed.122.264398

Chicago Style (17th ed.) Citation

S, Pathmanandavel, et al. "Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 64, no. 2 (2023): 221. https://doi.org/10.2967/jnumed.122.264398.

MLA (9th ed.) Citation

S, Pathmanandavel, et al. "Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol. 64, no. 2, 2023, p. 221, https://doi.org/10.2967/jnumed.122.264398.